

![]() |
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia |
|
Authors | ![]() | |
Published in | New England Journal of Medicine. 2016, vol. 375, no. 11, p. 1044-1053 | |
Abstract | Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial. | |
Keywords | Adolescent — Adult — Antigens, CD20/analysis — Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use — Disease-Free Survival — Female — Follow-Up Studies — Humans — Male — Middle Aged — Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/immunology — Prognosis — Remission Induction — Rituximab/administration & dosage/adverse effects — Young Adult | |
Identifiers | PMID: 27626518 | |
Full text | ||
Structures | ||
Research group | Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982) | |
Citation (ISO format) | MAURY, Sébastien et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. In: New England Journal of Medicine, 2016, vol. 375, n° 11, p. 1044-1053. doi: 10.1056/NEJMoa1605085 https://archive-ouverte.unige.ch/unige:99092 |